Development of an inactivated vaccine candidate for SARS-CoV-2
Top Cited Papers
Open Access
- 3 July 2020
- journal article
- research article
- Published by American Association for the Advancement of Science (AAAS) in Science
- Vol. 369 (6499), 77-81
- https://doi.org/10.1126/science.abc1932
Abstract
The coronavirus disease 2019 (COVID-19) pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has resulted in an unprecedented public health crisis. Because of the novelty of the virus, there are currently no SARS-CoV-2–specific treatments or vaccines available. Therefore, rapid development of effective vaccines against SARS-CoV-2 are urgently needed. Here, we developed a pilot-scale production of PiCoVacc, a purified inactivated SARS-CoV-2 virus vaccine candidate, which induced SARS-CoV-2–specific neutralizing antibodies in mice, rats, and nonhuman primates. These antibodies neutralized 10 representative SARS-CoV-2 strains, suggesting a possible broader neutralizing ability against other strains. Three immunizations using two different doses, 3 or 6 micrograms per dose, provided partial or complete protection in macaques against SARS-CoV-2 challenge, respectively, without observable antibody-dependent enhancement of infection. These data support the clinical development and testing of PiCoVacc for use in humans.Keywords
Funding Information
- National key research and development program (2020YFA0707500)
- Ten Thousand Talent Program and the NSFS Innovative Research Group (81921005)
This publication has 28 references indexed in Scilit:
- Passive Immunotherapy with Dromedary Immune Serum in an Experimental Animal Model for Middle East Respiratory Syndrome Coronavirus InfectionJournal of Virology, 2015
- IQ-TREE: A Fast and Effective Stochastic Algorithm for Estimating Maximum-Likelihood PhylogeniesMolecular Biology and Evolution, 2014
- Thyroid Cancer Risk Is Not Increased in Diabetic PatientsPLOS ONE, 2012
- Correction: Immunization with SARS Coronavirus Vaccines Leads to Pulmonary Immunopathology on Challenge with the SARS VirusPLOS ONE, 2012
- Immunization with SARS Coronavirus Vaccines Leads to Pulmonary Immunopathology on Challenge with the SARS VirusPLOS ONE, 2012
- Apilimod Inhibits the Production of IL-12 and IL-23 and Reduces Dendritic Cell Infiltration in PsoriasisPLOS ONE, 2012
- Safety of trivalent inactivated influenza vaccines in adults: Background for pandemic influenza vaccine safety monitoringVaccine, 2009
- Lung pathology of fatal severe acute respiratory syndromeThe Lancet, 2003
- On the analysis of psychometric functions: The Spearman-Kärber methodPerception & Psychophysics, 2001
- Inactivated poliovirus vaccine: past and present experienceVaccine, 1996